How This Works
Cerebrolysin is a multicomponent peptide preparation derived from porcine brain tissue, containing biologically active neuropeptides and amino acids with molecular weights below 10 kDa[1]. This low molecular weight allows it to cross the blood–brain barrier and exert neurotrophic effects similar to endogenous factors like nerve growth factor (NGF) and brain‑derived neurotrophic factor (BDNF)[1][2]. Preclinical studies demonstrate neuroprotective effects including reduced infarct size and improved recovery in ischemia models[4][5]. Human trials have examined its use in stroke, dementia, and traumatic brain injury with mixed but generally favorable tolerability profiles[2][3].
References
International Peptide Society
— Cerebrolysin Monograph: mechanism, pharmacology, and clinical applications (2018)
Alzheimer’s Drug Discovery Foundation
— Cerebrolysin cognitive vitality report: evidence synthesis and safety overview (2016)
Zhang et al., Med Sci Monit (PMC)
— Meta‑analysis of Cerebrolysin efficacy and safety in acute ischemic stroke (2017)
Kurkin et al., PLOS One
— Neuroprotective action of Cerebrolysin in acute/chronic brain ischemia in rats (2021)
Espinoza et al., Behav Brain Res (PubMed)
— Cerebrolysin neuroprotection and neurorepair in diabetic rat model (2024)
CDC
— Measurement safety: preventing unsafe measurement practices in clinical settings (2024)
WHO
— Measurement safety: best practices for healthcare providers guide (2016)
Ever Neuro Pharma
— Cerebrolysin measurement recommendation and storage specifications (SPC 2016)
NCBI Bookshelf
— handling reference: preparation, preparation, and site rotation
Drug Delivery Review (PMC)
— Pharmacologic considerations and best practices for preparation
Cognitive Frailty & Cerebrolysin Review (PMC)
— Evidence for peptidergic nootropics in age‑related cognitive decline
Neurotrophic Factors & Neurodegeneration (PMC)
— Role of NGF/BDNF pathways in neuroprotection and neuroplasticity